Cancer Therapy Advisor13h
FDA Expands Approval of Pluvicto in PSMA-Positive mCRPC
The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.
Cancer Therapy Advisor13h
Some Esophageal Cancer Patients May Be Able to Skip Surgery After CRT
Some patients with locally advanced esophageal cancer may be able to safely forgo esophagectomy after CRT, data suggest.
Cancer Therapy Advisor13h
Continuing With Pembrolizumab-Based Therapy Beyond Progression May Improve OS
Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that treatment.
Cancer Therapy Advisor13h
Five CDC Leaders Step Down
(HealthDay News) — Five leaders at the US Centers for Disease Control and Prevention (CDC) stepped down last week, according to The Associated Press, which confirmed the departures through 2 anonymous ...